Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025
Rhea-AI Summary
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, has scheduled its second quarter 2025 financial results announcement for Wednesday, July 30, 2025. The results will be released before market opening, followed by a conference call at 8:30 a.m. ET.
Investors can access the conference call via phone (toll-free: 1-800-717-1738 or international: 1-646-307-1865) using conference ID 48251. A live webcast and presentation materials will be available on Anika's investor relations website, with an archived version accessible after the call.
[]Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ANIK gained 0.45%, reflecting a mild positive market reaction. This price movement added approximately $737K to the company's valuation, bringing the market cap to $164M at that time.
Data tracked by StockTitan Argus on the day of publication.
BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 48251. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
When will Anika Therapeutics (ANIK) release Q2 2025 earnings?
How can investors join Anika's Q2 2025 earnings call?
What time is Anika's Q2 2025 earnings conference call?
Where can I find Anika's Q2 2025 earnings presentation materials?
